search
Back to results

A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer

Primary Purpose

Gastrointestinal Neoplasms, Cholangiocarcinoma, Pancreatic Neoplasms

Status
Active
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
BI 905711
Sponsored by
Boehringer Ingelheim
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Gastrointestinal Neoplasms

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

- a. Phase Ia (dose escalation only)

Histologically or cytologically confirmed, advanced unresectable or metastatic gastrointestinal cancers of following histologies:

  • Colorectal adenocarcinoma
  • Gastric adenocarcinoma
  • Esophageal adenocarcinoma
  • Pancreatic adenocarcinoma
  • Cholangiocarcinoma and gallbladder carcinoma
  • Small intestine adenocarcinoma b. Phase Ib (expansion phase)
  • Histologically or cytologically confirmed, advanced unresectable or metastatic colorectal adenocarcinoma.

    • Patient who has failed all available conventional therapies known to confer clinical benefit for their disease based on local approved standards. For patients with colorectal cancer, prior treatment with regorafenib or TAS-102 is optional.
    • Phase Ia (dose escalation) only: Patient with either measurable or non-measurable/non-evaluable disease.
    • Phase Ia (expanded cohort) and Phase Ib (expansion phase) only: At least one target lesion that can be accurately measured per RECIST v.1.1
    • Availability and willingness to provide an archived tumor tissue specimen and undergo tumor biopsy before treatment. Pre-treatment fresh tumor biopsy collections for biomarker analyses are considered optional in phase Ia and mandatory in phase Ib. Only nonsignificant risk procedures per the investigator's judgment will be used to obtain any biopsies specified in this study. In case a fresh tumor biopsy cannot be obtained due to before mentioned reasons an archived tumor tissue specimen obtained within ≤6 months of screening must be submitted. In case the patient undergoes baseline tumor biopsy, an archived tumor tissue specimen must be submitted regardless of the date of collection.
    • Adequate hepatic, renal and bone marrow functions as defined by all of the below:
  • Total bilirubin ≤ 1.5 x institutional Upper Level of Normal (ULN) (≤ 3 x institutional ULN for patient with Gilbert's syndrome)
  • ALT and AST ≤2.5 x institutional ULN (≤5 x institutional ULN for patients with known liver metastases)
  • Serum creatinine ≤1.5x institutional ULN. If creatinine is > 1.5 x ULN, patient is eligible if concurrent creatinine clearance ≥ 50 ml/min (>0.05 L/min) (measured or calculated by CKD-EPI formula or Japanese version of CKD-EPI formula for Japanese patients).
  • ANC ≥ 1.0x 10^9/L (≥ 1.0 x 10^3/μL, ≥ 1,000/mm3)
  • Platelets ≥ 100x10^9/ L (≥ 100 x 10^3/μL, ≥ 100 x 10^3/mm3)
  • Hemoglobin (Hb) ≥8.5 g/dl, ≥ 85 g/L, or ≥ 5.3 mmol/L (without transfusion within previous week)
  • Serum lipase ≤ 1.5 institutional ULN

    • Recovery from any adverse events according to Common Terminology Criteria for Adverse Events (CTCAE) v5.0 of previous anti-cancer therapies to baseline or CTCAE grade 1, except for alopecia CTCAE grade 2, sensory peripheral neuropathy CTCAE grade ≤ 2 or considered not clinically significant.
    • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
    • Life expectancy ≥ 3 months in the opinion of the investigator
    • Of legal adult age (according to local legislation) at screening
    • Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial.
    • Male or female patients. Women of childbearing potential (WOCBP) and men able to father a child must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly.

Exclusion Criteria:

  • Previous systemic anti-cancer therapy within the specified timeframe from the last dose intake to the first dose of trial treatment as shown below:

    • Any non-investigational drug, including anti-angiogenic antibodies (bevacizumab or ramucirumab) and anti-EGFR antibodies (cetuximab or panitumumab), within 14 days.
    • Any investigational drug or other antibodies including immune checkpoint inhibitors, within 28 days.
  • Radiation therapy within 4 weeks prior to start of treatment. However, palliative radiotherapy for symptomatic metastasis is allowed if completed within 2 weeks prior to start of treatment but must be discussed with the sponsor.
  • Any serious concomitant disease or medical condition affecting compliance with Trial requirements or which are considered relevant for the evaluation of the efficacy or safety of the trial drug, such as neurologic, psychiatric, infectious disease or active ulcers (gastro-intestinal (GI) tract, skin) or laboratory abnormality that may increase the risk associated with trial participation or trial drug administration, and in the judgment of the Investigator, would make the patient inappropriate for entry into the trial. Any history of stroke or myocardial infarction within 6 months prior to screening.
  • Known pathological condition of GI tract, liver and pancreas, excluding the disease under study, that may interfere with assessment of drug safety or may increase the risk of toxicity:

    • inflammatory bowel disease
    • chronic pancreatitis
    • other serious GI pathological conditions by judgment of the investigator e.g. autoimmune disease with GI involvement, unexplained active diarrhea CTCAE grade ≥2 according to CTCAE v5.0.
  • Known history of human immunodeficiency virus infection.
  • Any of the following laboratory evidence of hepatitis virus infection. Test results obtained in routine diagnostics are acceptable if done within 14 days before the informed consent date:

    • Positive results of hepatitis B surface (HBs) antigen
    • Presence of HBc antibody together with HBV-DNA
    • Presence of hepatitis C RNA
  • Active concomitant malignancies, other than the one treated in this trial.
  • Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes the patient an unreliable trial participant or unlikely to comply with the protocol requirements or not expected to complete the trial as scheduled.
  • Women who are pregnant, nursing, or who plan to become pregnant while in the trial; female patients who do not agree to the interruption of breast feeding from the start of study treatment to within 30 days after the last study treatment.
  • Presence of uncontrolled or symptomatic brain or subdural metastases. Inclusion of patients with brain metastases who have completed local therapy and are considered stable by the investigator, or with newly identified asymptomatic brain metastases at screening will be allowed. Use of corticosteroids is allowed if the dose was stable for at least 1 week before the baseline MRI.
  • Patients who are under judicial protection and patients who are legally institutionalized
  • Major surgery (major according to the investigator's assessment) performed within 3 weeks prior to treatment start or planned within 3 months after screening, e.g. hip replacement.
  • Any of the following cardiac criteria:

    • Resting corrected QT interval (QTc) >470 msec
    • Any clinically important abnormalities (as assessed by the Investigator) in rhythm, conduction, or morphology of resting ECGs, e.g., complete left bundle branch block, third degree heart block
    • Patients with an ejection fraction (EF) <50% or the lower limit of normal of the institutional standard will be excluded. Only in cases where the Investigator (or the treating physician or both) suspects cardiac disease with negative effect on the EF, will the EF be measured during screening using an appropriate method according to local standards to confirm eligibility (e.g., echocardiogram, multi-gated acquisition scan). A historic measurement of EF no older than 6 months prior to first administration of study drug can be accepted provided that there is clinical evidence that the EF value has not worsened since this measurement in the opinion of the Investigator or of the treating physician or both.
  • Known hypersensitivity to the trial medication and/or its components i.e. polysorbate 20, sodium citrate, lysine hydrochloride, sucrose, citric acid.

Sites / Locations

  • Yale Cancer Center
  • Memorial Sloan-Kettering Cancer Center
  • The University of Texas MD Anderson Cancer Center
  • START South Texas Accelerated Research Therapeutics, LLC
  • Brussels - UNIV Saint-Luc
  • UZ Leuven
  • Beijing Cancer Hospital
  • The Sixth Affiliated Hospital of Sun Yat-sen University
  • HOP Jean Minjoz
  • CTR Leon Berard
  • HOP la Milétrie
  • CTR Eugène Marquis
  • Universitätsklinikum Mannheim GmbH
  • National Cancer Center Hospital East
  • Korea University Anam Hospital
  • Hospital Vall d'Hebron
  • Hospital Ramón y Cajal
  • Hospital Clínico de Valencia

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

Phase Ia: BI 905711 - dose escalation

Phase Ib: BI 905711 - dose level 1

Phase Ib: BI 905711 - dose level 2

Phase Ib: BI 905711 - dose level 3

Phase Ib: BI 905711 - dose level 4

Arm Description

Outcomes

Primary Outcome Measures

Phase Ia - Maximum tolerated dose (MTD) defined as the highest dose with less than 25% risk of the true DLT rate being equal or above 33% during the MTD evaluation period
Phase Ia - Number of patients with DLTs in the MTD evaluation period
Phase Ib - Objective response based on RECIST 1.1 criteria
Objective response is defined as best overall response of complete response or partial response, where best overall response is the best response recorded from the start of the study treatment until the earliest of disease progression, death or last evaluable tumor assessment and before start of subsequent anti-cancer therapy
Phase Ib - Progression-free survival (PFS) is defined as the time from first treatment administration until tumor progression according to RECIST 1.1 or death from any cause, whichever occurs earlier.

Secondary Outcome Measures

Phase Ia - Cmax: maximum measured concentration of BI 905711 in plasma
Phase Ia - AUC0-t2: area under the concentration-time curve of BI 905711 in plasma
Phase Ia - Objective response based on RECIST 1.1 criteria in patients with measurable disease
Phase Ib - Radiological (CT Scan) tumor shrinkage, defined as the difference between the minimum post-baseline sum of longest diameters of target lesions and the baseline sum of longest diameters of the same set of target lesions according to RECIST 1.1
Phase Ib -The duration of overall response is measured from the time measurement criteria are first met for CR/PR until the first date that recurrent or progressive disease is objectively documented according to RECIST 1.1
Phase Ib - Number of patients with treatment-emergent adverse events (AE)s
Phase Ib - Disease control, defined as CR, PR, or stable disease according to RECIST 1.1 from the start of treatment until the earliest of progression disease, death or last evaluable tumor assessment and before start of subsequent anti-cancer therapy
Phase Ib - Cmax: maximum measured concentration of BI 905711 in plasma
Phase Ib - AUC0-t2: area under the concentration-time curve of BI 905711 in plasma

Full Information

First Posted
October 22, 2019
Last Updated
September 22, 2023
Sponsor
Boehringer Ingelheim
search

1. Study Identification

Unique Protocol Identification Number
NCT04137289
Brief Title
A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer
Official Title
A First-in-human Phase Ia/b, Open Label, Multicentre, Dose Escalation Study of BI 905711 in Patients With Advanced Gastrointestinal Cancers
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
March 11, 2020 (Actual)
Primary Completion Date
November 22, 2023 (Anticipated)
Study Completion Date
November 22, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boehringer Ingelheim

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Phase Ia - Explore safety and establish the maximum tolerated dose (MTD)/recommended dose levels for phase Ib expansion phase of BI 905711 based on the frequency of patients experiencing dose limiting toxicities (DLTs) during the MTD evaluation period. The MTD evaluation period is defined as the first two treatment cycles (from first dose administration until the day preceding the third dose administration or end of REP in case of discontinuation before start of Cycle 3). Phase Ia - Explore pharmacokinetics/pharmacodynamics, and efficacy to guide the determination of a potentially effective dose range for phase Ib in the absence of MTD. Phase Ib - Evaluate efficacy and safety of BI 905711 at a potentially effective dose range and determine the Recommended Phase 2 Dose (RP2D)

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gastrointestinal Neoplasms, Cholangiocarcinoma, Pancreatic Neoplasms

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Model Description
Phase Ia: Dose escalation (non randomised, 1 arm) Phase Ib: Dose expansion (randomised, 4 arms)
Masking
None (Open Label)
Allocation
Randomized
Enrollment
110 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Phase Ia: BI 905711 - dose escalation
Arm Type
Experimental
Arm Title
Phase Ib: BI 905711 - dose level 1
Arm Type
Experimental
Arm Title
Phase Ib: BI 905711 - dose level 2
Arm Type
Experimental
Arm Title
Phase Ib: BI 905711 - dose level 3
Arm Type
Experimental
Arm Title
Phase Ib: BI 905711 - dose level 4
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
BI 905711
Intervention Description
BI 905711
Primary Outcome Measure Information:
Title
Phase Ia - Maximum tolerated dose (MTD) defined as the highest dose with less than 25% risk of the true DLT rate being equal or above 33% during the MTD evaluation period
Time Frame
Up to 28 days
Title
Phase Ia - Number of patients with DLTs in the MTD evaluation period
Time Frame
Up to 28 days
Title
Phase Ib - Objective response based on RECIST 1.1 criteria
Description
Objective response is defined as best overall response of complete response or partial response, where best overall response is the best response recorded from the start of the study treatment until the earliest of disease progression, death or last evaluable tumor assessment and before start of subsequent anti-cancer therapy
Time Frame
Up to 107 days
Title
Phase Ib - Progression-free survival (PFS) is defined as the time from first treatment administration until tumor progression according to RECIST 1.1 or death from any cause, whichever occurs earlier.
Time Frame
Up to 107 days
Secondary Outcome Measure Information:
Title
Phase Ia - Cmax: maximum measured concentration of BI 905711 in plasma
Time Frame
Up to day 1 and up to day 19
Title
Phase Ia - AUC0-t2: area under the concentration-time curve of BI 905711 in plasma
Time Frame
Up to day 1 and up to day 19
Title
Phase Ia - Objective response based on RECIST 1.1 criteria in patients with measurable disease
Time Frame
Up to 107 days
Title
Phase Ib - Radiological (CT Scan) tumor shrinkage, defined as the difference between the minimum post-baseline sum of longest diameters of target lesions and the baseline sum of longest diameters of the same set of target lesions according to RECIST 1.1
Time Frame
Up to 107 days
Title
Phase Ib -The duration of overall response is measured from the time measurement criteria are first met for CR/PR until the first date that recurrent or progressive disease is objectively documented according to RECIST 1.1
Time Frame
Up to 107 days
Title
Phase Ib - Number of patients with treatment-emergent adverse events (AE)s
Time Frame
Up to 107 days
Title
Phase Ib - Disease control, defined as CR, PR, or stable disease according to RECIST 1.1 from the start of treatment until the earliest of progression disease, death or last evaluable tumor assessment and before start of subsequent anti-cancer therapy
Time Frame
Baseline and up to 107 days
Title
Phase Ib - Cmax: maximum measured concentration of BI 905711 in plasma
Time Frame
Up to day 1 and up to day 19
Title
Phase Ib - AUC0-t2: area under the concentration-time curve of BI 905711 in plasma
Time Frame
Up to day 1 and up to day 19

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: - a. Phase Ia (dose escalation only) Histologically or cytologically confirmed, advanced unresectable or metastatic gastrointestinal cancers of following histologies: Colorectal adenocarcinoma Gastric adenocarcinoma Esophageal adenocarcinoma Pancreatic adenocarcinoma Cholangiocarcinoma and gallbladder carcinoma Small intestine adenocarcinoma b. Phase Ib (expansion phase) Histologically or cytologically confirmed, advanced unresectable or metastatic colorectal adenocarcinoma. Patient who has failed all available conventional therapies known to confer clinical benefit for their disease based on local approved standards. For patients with colorectal cancer, prior treatment with regorafenib or TAS-102 is optional. Phase Ia (dose escalation) only: Patient with either measurable or non-measurable/non-evaluable disease. Phase Ia (expanded cohort) and Phase Ib (expansion phase) only: At least one target lesion that can be accurately measured per RECIST v.1.1 Availability and willingness to provide an archived tumor tissue specimen and undergo tumor biopsy before treatment. Pre-treatment fresh tumor biopsy collections for biomarker analyses are considered optional in phase Ia and mandatory in phase Ib. Only nonsignificant risk procedures per the investigator's judgment will be used to obtain any biopsies specified in this study. In case a fresh tumor biopsy cannot be obtained due to before mentioned reasons an archived tumor tissue specimen obtained within ≤6 months of screening must be submitted. In case the patient undergoes baseline tumor biopsy, an archived tumor tissue specimen must be submitted regardless of the date of collection. Adequate hepatic, renal and bone marrow functions as defined by all of the below: Total bilirubin ≤ 1.5 x institutional Upper Level of Normal (ULN) (≤ 3 x institutional ULN for patient with Gilbert's syndrome) ALT and AST ≤2.5 x institutional ULN (≤5 x institutional ULN for patients with known liver metastases) Serum creatinine ≤1.5x institutional ULN. If creatinine is > 1.5 x ULN, patient is eligible if concurrent creatinine clearance ≥ 50 ml/min (>0.05 L/min) (measured or calculated by CKD-EPI formula or Japanese version of CKD-EPI formula for Japanese patients). ANC ≥ 1.0x 10^9/L (≥ 1.0 x 10^3/μL, ≥ 1,000/mm3) Platelets ≥ 100x10^9/ L (≥ 100 x 10^3/μL, ≥ 100 x 10^3/mm3) Hemoglobin (Hb) ≥8.5 g/dl, ≥ 85 g/L, or ≥ 5.3 mmol/L (without transfusion within previous week) Serum lipase ≤ 1.5 institutional ULN Recovery from any adverse events according to Common Terminology Criteria for Adverse Events (CTCAE) v5.0 of previous anti-cancer therapies to baseline or CTCAE grade 1, except for alopecia CTCAE grade 2, sensory peripheral neuropathy CTCAE grade ≤ 2 or considered not clinically significant. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 Life expectancy ≥ 3 months in the opinion of the investigator Of legal adult age (according to local legislation) at screening Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial. Male or female patients. Women of childbearing potential (WOCBP) and men able to father a child must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. Exclusion Criteria: Previous systemic anti-cancer therapy within the specified timeframe from the last dose intake to the first dose of trial treatment as shown below: Any non-investigational drug, including anti-angiogenic antibodies (bevacizumab or ramucirumab) and anti-EGFR antibodies (cetuximab or panitumumab), within 14 days. Any investigational drug or other antibodies including immune checkpoint inhibitors, within 28 days. Radiation therapy within 4 weeks prior to start of treatment. However, palliative radiotherapy for symptomatic metastasis is allowed if completed within 2 weeks prior to start of treatment but must be discussed with the sponsor. Any serious concomitant disease or medical condition affecting compliance with Trial requirements or which are considered relevant for the evaluation of the efficacy or safety of the trial drug, such as neurologic, psychiatric, infectious disease or active ulcers (gastro-intestinal (GI) tract, skin) or laboratory abnormality that may increase the risk associated with trial participation or trial drug administration, and in the judgment of the Investigator, would make the patient inappropriate for entry into the trial. Any history of stroke or myocardial infarction within 6 months prior to screening. Known pathological condition of GI tract, liver and pancreas, excluding the disease under study, that may interfere with assessment of drug safety or may increase the risk of toxicity: inflammatory bowel disease chronic pancreatitis other serious GI pathological conditions by judgment of the investigator e.g. autoimmune disease with GI involvement, unexplained active diarrhea CTCAE grade ≥2 according to CTCAE v5.0. Known history of human immunodeficiency virus infection. Any of the following laboratory evidence of hepatitis virus infection. Test results obtained in routine diagnostics are acceptable if done within 14 days before the informed consent date: Positive results of hepatitis B surface (HBs) antigen Presence of HBc antibody together with HBV-DNA Presence of hepatitis C RNA Active concomitant malignancies, other than the one treated in this trial. Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, makes the patient an unreliable trial participant or unlikely to comply with the protocol requirements or not expected to complete the trial as scheduled. Women who are pregnant, nursing, or who plan to become pregnant while in the trial; female patients who do not agree to the interruption of breast feeding from the start of study treatment to within 30 days after the last study treatment. Presence of uncontrolled or symptomatic brain or subdural metastases. Inclusion of patients with brain metastases who have completed local therapy and are considered stable by the investigator, or with newly identified asymptomatic brain metastases at screening will be allowed. Use of corticosteroids is allowed if the dose was stable for at least 1 week before the baseline MRI. Patients who are under judicial protection and patients who are legally institutionalized Major surgery (major according to the investigator's assessment) performed within 3 weeks prior to treatment start or planned within 3 months after screening, e.g. hip replacement. Any of the following cardiac criteria: Resting corrected QT interval (QTc) >470 msec Any clinically important abnormalities (as assessed by the Investigator) in rhythm, conduction, or morphology of resting ECGs, e.g., complete left bundle branch block, third degree heart block Patients with an ejection fraction (EF) <50% or the lower limit of normal of the institutional standard will be excluded. Only in cases where the Investigator (or the treating physician or both) suspects cardiac disease with negative effect on the EF, will the EF be measured during screening using an appropriate method according to local standards to confirm eligibility (e.g., echocardiogram, multi-gated acquisition scan). A historic measurement of EF no older than 6 months prior to first administration of study drug can be accepted provided that there is clinical evidence that the EF value has not worsened since this measurement in the opinion of the Investigator or of the treating physician or both. Known hypersensitivity to the trial medication and/or its components i.e. polysorbate 20, sodium citrate, lysine hydrochloride, sucrose, citric acid.
Facility Information:
Facility Name
Yale Cancer Center
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06511
Country
United States
Facility Name
Memorial Sloan-Kettering Cancer Center
City
New York
State/Province
New York
ZIP/Postal Code
10022
Country
United States
Facility Name
The University of Texas MD Anderson Cancer Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
START South Texas Accelerated Research Therapeutics, LLC
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
Facility Name
Brussels - UNIV Saint-Luc
City
Bruxelles
ZIP/Postal Code
1200
Country
Belgium
Facility Name
UZ Leuven
City
Leuven
ZIP/Postal Code
3000
Country
Belgium
Facility Name
Beijing Cancer Hospital
City
Beijing
ZIP/Postal Code
100142
Country
China
Facility Name
The Sixth Affiliated Hospital of Sun Yat-sen University
City
Guangzhou
ZIP/Postal Code
510655
Country
China
Facility Name
HOP Jean Minjoz
City
Besançon
ZIP/Postal Code
25030
Country
France
Facility Name
CTR Leon Berard
City
Lyon
ZIP/Postal Code
69373
Country
France
Facility Name
HOP la Milétrie
City
Poitiers
ZIP/Postal Code
86021
Country
France
Facility Name
CTR Eugène Marquis
City
Rennes
ZIP/Postal Code
35042
Country
France
Facility Name
Universitätsklinikum Mannheim GmbH
City
Mannheim
ZIP/Postal Code
68167
Country
Germany
Facility Name
National Cancer Center Hospital East
City
Chiba, Kashiwa
ZIP/Postal Code
277-8577
Country
Japan
Facility Name
Korea University Anam Hospital
City
Seoul
ZIP/Postal Code
02841
Country
Korea, Republic of
Facility Name
Hospital Vall d'Hebron
City
Barcelona
ZIP/Postal Code
08035
Country
Spain
Facility Name
Hospital Ramón y Cajal
City
Madrid
ZIP/Postal Code
28034
Country
Spain
Facility Name
Hospital Clínico de Valencia
City
Valencia
ZIP/Postal Code
46010
Country
Spain

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website. The data shared are the raw clinical study data sets.
IPD Sharing Time Frame
After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.
IPD Sharing Access Criteria
For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.
IPD Sharing URL
https://www.mystudywindow.com/msw/datasharing
Citations:
PubMed Identifier
33037135
Citation
Garcia-Martinez JM, Wang S, Weishaeupl C, Wernitznig A, Chetta P, Pinto C, Ho J, Dutcher D, Gorman PN, Kroe-Barrett R, Rinnenthal J, Giragossian C, Impagnatiello MA, Tirapu I, Hilberg F, Kraut N, Pearson M, Kuenkele KP. Selective Tumor Cell Apoptosis and Tumor Regression in CDH17-Positive Colorectal Cancer Models using BI 905711, a Novel Liver-Sparing TRAILR2 Agonist. Mol Cancer Ther. 2021 Jan;20(1):96-108. doi: 10.1158/1535-7163.MCT-20-0253. Epub 2020 Oct 9.
Results Reference
derived
Links:
URL
https://www.mystudywindow.com
Description
Related Info

Learn more about this trial

A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer

We'll reach out to this number within 24 hrs